BGNE - BeiGene, Ltd.
| Previous Close | 122.91 |
| Open | 122.90 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 118.70 - 122.90 |
| 52 Week Range | 105.19 - 194.56 |
| Volume | 163,014 |
| Avg. Volume | 290,580 |
| Market Cap | 7.162B |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.83 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 181.39 |
- Simply Wall St.•2 days ago
Did You Miss BeiGene's (NASDAQ:BGNE) Whopping 327% Share Price Gain?
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a...
- Motley Fool•5 days ago
Here's Why BeiGene Lost 11.6% in the First Half of 2019
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
- Motley Fool•8 days ago
3 Top Chinese Stocks to Watch in July
Technology, drugs, and energy... here are three Chinese stocks from three different industries that you should be watching today
- GlobeNewswire•9 days ago
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the China National Medical Products Administration (NMPA, formerly known as the CFDA) has granted priority review status to the supplemental new drug application (sNDA) for tislelizumab, an investigational Fc-engineered anti-PD-1 antibody, for patients with previously treated locally-advanced or metastatic urothelial carcinoma (UC). “This is our second priority review granted by the NMPA for tislelizumab, and our first for a solid tumor indication and first in China for a PD-1/PDL1 antibody for bladder cancer,” said Wendy Yan, Senior Vice President, Global Head of Regulatory Affairs, at BeiGene.
- GlobeNewswire•19 days ago
BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following its application to the Stock Exchange of Hong Kong Limited (HKEX), the Company has been approved for listing under Rule 8.05(3) as a company that meets specified revenue and market capitalization thresholds. BeiGene initially listed on the HKEX on August 8, 2018 under the biotech chapter (Chapter 18A) of the Listing Rules. The Company now satisfies the revenue and market capitalization tests for listing outside of the biotech chapter.
- Motley Fool•21 days ago
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
Some of the drugs aren't going to survive this marriage.
- Insider Monkey•21 days ago
Here’s What Hedge Funds Think About BeiGene, Ltd. (BGNE)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- GlobeNewswire•27 days ago
BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)
CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•27 days ago
BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)
CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•28 days ago
BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)
CAMBRIDGE, Mass. and BEIJING, China, June 19, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•29 days ago
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the formation of MapKure, LLC, a newly created entity that is jointly owned by BeiGene and SpringWorks. MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
- GlobeNewswire•last month
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has entered into a mutual agreement with Celgene Corporation to terminate the parties’ global collaboration for tislelizumab, BeiGene’s investigational anti-PD-1 antibody, in advance of the pending acquisition of Celgene by Bristol-Myers Squibb. In connection with the termination, Celgene has agreed to pay $150 million to BeiGene. “Our collaboration with Celgene was instrumental for the late-stage clinical development of tislelizumab and has provided us with significant resources to continue our broad clinical program,” said John V. Oyler, Co-Founder, Chief Executive Officer, and Chairman of BeiGene.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
- GlobeNewswire•last month
BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
First Preliminary Data from Exploratory MYD88WT Patient Cohort in Phase 3 Trial in Waldenström’s Macroglobulinemia (WM); Updated Phase 1/2 WM Data; and Pooled Safety Data.
- GlobeNewswire•last month
BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced updated results from a pivotal Phase 2 study of tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in a poster at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam. “The encouraging clinical results from this study further support our new drug application for tislelizumab in patients with R/R cHL that is currently under priority review in China,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene.
- GlobeNewswire•last month
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Simply Wall St.•last month
Is BeiGene, Ltd. (NASDAQ:BGNE) As Strong As Its Balance Sheet Indicates?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as BeiGene...
- GlobeNewswire•last month
BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. and BEIJING, China, June 05, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•last month
BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Biotechnology Innovation Organization (BIO) has elected John V. Oyler, Co-Founder, Chief Executive Officer, and Chairman of BeiGene, to its Board of Directors as well as to its Health Section Governing Board.
- GlobeNewswire•2 months ago
BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced preliminary results of tislelizumab, its investigational anti-PD-1 inhibitor, in Chinese patients with nasopharyngeal cancer (NPC) that were presented in a poster at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31 - June 4, 2019. “We believe that these data further support the broad development program for tislelizumab, including the global Phase 3 double-blind trial of tislelizumab in combination with chemotherapy in comparison to placebo with chemotherapy as a first-line treatment for patients with recurrent or metastatic NPC,” said Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene.
- Benzinga•2 months ago
The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
- GlobeNewswire•2 months ago
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•2 months ago
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the China National Medical Products Administration (NMPA, formerly known as CFDA) has accepted a supplemental new drug application (sNDA) for tislelizumab, an investigational anti-PD-1 antibody, for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma (UC). “The development program for tislelizumab is achieving its milestones swiftly with our first solid-tumor filing for patients with previously treated urothelial carcinoma following our initial filing last year for patients with relapsed/refractory classical Hodgkin’s lymphoma.
- GlobeNewswire•2 months ago
BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Reuters•2 months ago
BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
May 10 (Reuters) - Beigene Ltd: * QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION * QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION Source text for Eikon: ...
